HAEMATO focuses on the trading of generics for cancer treatment. Therefore the product range consists of common active substances used in the oncology.

Pharmaceuticals with new innovative active ingredients are normally patent protected for 10 to 15 years. After the expiry, other pharmaceutical companies can produce drugs with the same active ingredients. These are called generics.

After such a generic product has entered the market, a fierce competition takes place, that can result in price drops of up to 50%. A look at the figures from 2013 stresses the importance of generics in the German healthcare system: According to ProGenerics e.V. 12.3 billion euros were saved by the public healthcare insurance companies due to the use of generics.

Here you can see which oncological generics you can get from HAEMATO.


Die HAEMATO AG ist ein börsennotiertes pharmazeutisches Unternehmen mit Fo-kus auf die Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel...


IFRS-Ergebnis Q1 2017, Umsatz 67,9 Mio. Euro (Vorjahresperiode: 67,9 Mio. Euro), EBIT 2,8 Mio. Euro (Vorjahresperiode: 3,5 Mio. Euro)...


2016: Vorläufiges IFRS-Ergebnis, Umsatzwachstum 20% auf 275,6 Mio. Euro, EBIT-Wachstum (operatives Ergebnis) 63% auf 13,4 Mio. Euro;...

Order service - Telephone: +49 30 677 98 67 60
Aktuelle News